Zachary Yerushalmi

We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. Were a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening. Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes. In August 2018, we announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. We also has several pilot programmes in development within UK and US healthcare systems. Our team is a multi-disciplinary group focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 90 people, including genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK) and Boston (US).

Ultromics pioneers precision heart failure detection. Our groundbreaking platform, EchoGo®, is revolutionizing the diagnosis of heart failure using artificial intelligence and cardiac ultrasound. Our technology empowers clinicians to make precise, efficient, and accurate assessments, drawing from the largest known heart disease dataset in echocardiography. We target challenging cardiac diseases, starting with HFpEF, to support timely diagnosis and early intervention. In collaboration with the Mayo Clinic, Johnson & Johnson, and Pfizer, we are continuously developing innovative diagnostic tools aimed at halting the progression of heart failure. Learn more: https://www.ultromics.com/. Follow Ultromics on social media for the latest news, X: https://x.com/ultromics, LinkedIn: https://www.linkedin.com/company/ultromics/.

Elevate Quantum is a Designated TechHub by the US Department of Commerce Economic Development Administration. A public-private consortium with more than 70 member organizations, Elevate Quantum works to ensure Colorado and Mountain West retains its role as national and international leader in quantum technologies and quantum information science. We help turn cutting-edge research into world-changing technologies, foster a vibrant startup and scale-up ecosystem, and build a diverse and inclusive workforce.

Intellectual Ventures is a global invention and investment business that creates, incubates and commercializes impactful inventions. Led by avid inventor and technology leader Nathan Myhrvold, IV has created more than a dozen companies with the power to transform industries. At the edge of technological advances to serve global markets, we work with the world’s top inventors to push innovation forward.

Here at Living Optics we are developing a pioneering hyperspectral imaging camera for the mass market. Our VIS-NIR snapshot HSI camera enables researchers and computer vision developers to capture data in real time at video frame rates and access information invisible to human eyes and/or conventional cameras. Our unique approach to hyperspectral imaging combines patented optical methods, built-from-scratch neural networks, and a small dose of pure maths. We’re well on our way to radically democratise and miniaturise hyperspectral systems, which have long been confined to research labs. Since being spun out from the Physics department of the University of Oxford in 2020, we have been developing the complex engineering and software applications ahead of our product launch in 2023. In September 2022 we announced our Series A £20m investment from https://oxfordscienceenterprises.com/, https://www.foresightwilliams.co.uk/, https://www.oxfordinvestmentconsultants.com/ and https://octopusventures.com/. We have a remote friendly, global team. At Living optics, we are fiercely proud of our talented workforce, whose creativity, tenacity and skills have enabled us to evolve into a successful, well-funded and rapidly growing company in just a few years. We strive to be an outstanding place to work – by maintaining a positive and inclusive culture, offering competitive salaries and benefits, encouraging ongoing training and development, plus, of course, plenty of other perks.

We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. Were a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalized estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening. Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes. In August 2018, we announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. We also has several pilot programmes in development within UK and US healthcare systems. Our team is a multi-disciplinary group focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 90 people, including genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK) and Boston (US).